{
  "verifier_model": "Qwen/Qwen1.5-1.8B-Chat",
  "quantized": false,
  "total_queries_processed": 10,
  "correctly_chosen_by_logprob": 8,
  "accuracy_percentage": 80.0,
  "queries_with_scoring_errors": 0,
  "response_files_used": [
    "Qwen_Qwen2.5-1.5B-Instruct_responses.jsonl",
    "dummy_model_responses.jsonl",
    "Qwen_Qwen2.5-3B-Instruct_responses.jsonl",
    "Qwen_Qwen2.5-7B-Instruct_responses.jsonl"
  ],
  "original_data_file": "/teamspace/studios/this_studio/llm_evaluation/examples/longhealth_semantic_filtering/data/processed/longhealth_cleaned.jsonl",
  "evaluation_details": [
    {
      "id": "patient_01_q0",
      "correct_answer_letter": "D",
      "best_response_by_logprob": {
        "id": "patient_01_q0",
        "generated_text": "D: Vincristine is not part of the current treatment regimen for Mrs. Sample's DLBCL. The text lists the current treatment as \"R-Pola-CHP regimen q21\", which includes Polatuzumab ved",
        "model_name": "Qwen/Qwen2.5-7B-Instruct",
        "generation_params": {
          "temperature": 0.7,
          "max_new_tokens": 50,
          "top_p": 0.9,
          "index": 0
        },
        "verifier_avg_nll": 1.3277480602264404
      },
      "chosen_letter_by_logprob": "D",
      "is_correct": true,
      "min_avg_nll": 1.3277480602264404
    },
    {
      "id": "patient_01_q1",
      "correct_answer_letter": "D",
      "best_response_by_logprob": {
        "id": "patient_01_q1",
        "generated_text": "2-vessel CHD: Mrs. Sample has 3-vessel CHD.\nTo determine which of the given options is NOT accurate based on the provided information, let's analyze each option step by step:\n\nA: She has 2-vessel",
        "model_name": "Qwen/Qwen2.5-1.5B-Instruct",
        "generation_params": {
          "temperature": 0.7,
          "max_new_tokens": 50,
          "top_p": 0.9,
          "index": 0
        },
        "verifier_avg_nll": 1.4918876886367798
      },
      "chosen_letter_by_logprob": null,
      "is_correct": false,
      "min_avg_nll": 1.4918876886367798
    },
    {
      "id": "patient_01_q2",
      "correct_answer_letter": "A",
      "best_response_by_logprob": {
        "id": "patient_01_q2",
        "generated_text": "A: Primary progressive type of multiple sclerosis (ID 03/02)\nBased on the provided context, Mrs. Sample suffers from a primary progressive type of multiple sclerosis (ID 03/02). Therefore, the correct option is",
        "model_name": "Qwen/Qwen2.5-7B-Instruct",
        "generation_params": {
          "temperature": 0.7,
          "max_new_tokens": 50,
          "top_p": 0.9,
          "index": 0
        },
        "verifier_avg_nll": 1.0216246843338013
      },
      "chosen_letter_by_logprob": "A",
      "is_correct": true,
      "min_avg_nll": 1.0216246843338013
    },
    {
      "id": "patient_01_q3",
      "correct_answer_letter": "B",
      "best_response_by_logprob": {
        "id": "patient_01_q3",
        "generated_text": "B: Fingolimod 0.5mg, 1 capsule at bedtime, Note: Take a break as directed\nAnswer: B: Fingolimod 0.5mg, 1 capsule at bedtime, Note:",
        "model_name": "Qwen/Qwen2.5-7B-Instruct",
        "generation_params": {
          "temperature": 0.7,
          "max_new_tokens": 50,
          "top_p": 0.9,
          "index": 0
        },
        "verifier_avg_nll": 1.4345635175704956
      },
      "chosen_letter_by_logprob": "B",
      "is_correct": true,
      "min_avg_nll": 1.4345635175704956
    },
    {
      "id": "patient_01_q4",
      "correct_answer_letter": "D",
      "best_response_by_logprob": {
        "id": "patient_01_q4",
        "generated_text": "D: 6 cycles of R-Pola-CHP\n\nThe oncology board recommends six cycles of the R-Pola-CHP regimen for Mrs. Sample, indicating the continuation of the current treatment plan without further modifications. This recommendation is based",
        "model_name": "Qwen/Qwen2.5-1.5B-Instruct",
        "generation_params": {
          "temperature": 0.7,
          "max_new_tokens": 50,
          "top_p": 0.9,
          "index": 0
        },
        "verifier_avg_nll": 1.4540261030197144
      },
      "chosen_letter_by_logprob": "D",
      "is_correct": true,
      "min_avg_nll": 1.4540261030197144
    },
    {
      "id": "patient_01_q5",
      "correct_answer_letter": "C",
      "best_response_by_logprob": {
        "id": "patient_01_q5",
        "generated_text": "C: Thoracic vertebra 10\nBased on the context provided, the metastasis that was surgically addressed is located at the thoracic vertebra 10. The relevant text from the initial update is as follows:\n\n**Pathology",
        "model_name": "Qwen/Qwen2.5-7B-Instruct",
        "generation_params": {
          "temperature": 0.7,
          "max_new_tokens": 50,
          "top_p": 0.9,
          "index": 0
        },
        "verifier_avg_nll": 1.8210464715957642
      },
      "chosen_letter_by_logprob": "C",
      "is_correct": true,
      "min_avg_nll": 1.8210464715957642
    },
    {
      "id": "patient_01_q6",
      "correct_answer_letter": "A",
      "best_response_by_logprob": {
        "id": "patient_01_q6",
        "generated_text": "A: The CT scan of Mrs. Sample's whole body on 01/09/2017 used Omnipaque 320 for contrast enhancement. This is indicated in the context provided, where it states \"Omn",
        "model_name": "Qwen/Qwen2.5-3B-Instruct",
        "generation_params": {
          "temperature": 0.7,
          "max_new_tokens": 50,
          "top_p": 0.9,
          "index": 0
        },
        "verifier_avg_nll": 1.6735996007919312
      },
      "chosen_letter_by_logprob": "A",
      "is_correct": true,
      "min_avg_nll": 1.6735996007919312
    },
    {
      "id": "patient_01_q7",
      "correct_answer_letter": "B",
      "best_response_by_logprob": {
        "id": "patient_01_q7",
        "generated_text": "B: MR Spine plain + post-contrast from 12/20/2016, MR Head 3D unenhanced + contrast from 12/19/2016, CT Thoracic Sp",
        "model_name": "Qwen/Qwen2.5-7B-Instruct",
        "generation_params": {
          "temperature": 0.7,
          "max_new_tokens": 50,
          "top_p": 0.9,
          "index": 0
        },
        "verifier_avg_nll": 0.3082251250743866
      },
      "chosen_letter_by_logprob": "B",
      "is_correct": true,
      "min_avg_nll": 0.3082251250743866
    },
    {
      "id": "patient_01_q8",
      "correct_answer_letter": "E",
      "best_response_by_logprob": {
        "id": "patient_01_q8",
        "generated_text": "**B: The patient started taking Pregabalin 75 mg, 1-0-1-0**.\n\nAnswer: **B: The patient started taking Pregabalin 75 mg, 1-0-1",
        "model_name": "Qwen/Qwen2.5-7B-Instruct",
        "generation_params": {
          "temperature": 0.7,
          "max_new_tokens": 50,
          "top_p": 0.9,
          "index": 0
        },
        "verifier_avg_nll": 1.476089358329773
      },
      "chosen_letter_by_logprob": null,
      "is_correct": false,
      "min_avg_nll": 1.476089358329773
    },
    {
      "id": "patient_01_q9",
      "correct_answer_letter": "B",
      "best_response_by_logprob": {
        "id": "patient_01_q9",
        "generated_text": "B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake.\n: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. The dosage of",
        "model_name": "Qwen/Qwen2.5-3B-Instruct",
        "generation_params": {
          "temperature": 0.7,
          "max_new_tokens": 50,
          "top_p": 0.9,
          "index": 0
        },
        "verifier_avg_nll": 2.0685644149780273
      },
      "chosen_letter_by_logprob": "B",
      "is_correct": true,
      "min_avg_nll": 2.0685644149780273
    }
  ]
}